Amplifying Data Science Tools for End-to-End eClinical Solutions

Podcast, Videos


Andreas Weber, Group CEO at EvidentIQ, sat down with me to discuss hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing customer demand across clinical operations and clinical data management, plus much more!

Here is a sneak peek of our conversation:

Q: Let’s actually pick apart or build the story flow, if you will, of a company, maybe they’re new in the whole decentralized clinical trial space and they want to start investigating options that are available to them. At a very high level, there is a myriad of companies that they have the opportunity to interact and work with, to help them solve their virtual trial question. Tell us a little bit about why EvidentIQ stands out from the crowd. What is it that you are going to do differently for that company?

A: First of all, I think it’s all about deciding what elements of a trial can be delivered in a virtual mode. This is actually where we are coming in. We are, first of all, consulting our customers because, at the end of the day, the verge has changed considerably from this quantum perspective. All of a sudden, it was impossible all the more for our patients to come to the sites. It’s very important as well to look at what makes sense and what doesn’t make sense.

My view and my company’s view are quite clear that the full adoption of virtual trials will stay and take some time. It will not happen in the next month and will probably not even happen in the next twenty years. What happens until then are companies will actually look at a model which is a hybrid model. That means some elements of the trials will be conducted in virtual mode and other elements of the trials will actually be conducted how it’s been done before COVID, meaning patients will go to the sites and we will monitor at the sites.

What makes us unique in EvidentIQ is that we start very early in the process. First of all, we are looking at the product or we’re looking at the endpoints together with our customers. We have a great scientific team in-house and they would actually tell the customer, “Look, in our view of the trial should be split into a few virtual elements and maybe some more traditional elements. That’s actually the first point. The second point is also to realize what technology is needed in order to conduct those elements that can be delivered virtually, meaning in virtual mode.

We are quite open and we are very flexible. We don’t want to overload our customers by maybe selling a big platform to them where they only need some sort of tiny elements of it. We will look in a most efficient way how we can actually cover those virtual elements of the trial and that is basically a proposal that we would make to our customers. Once they have accepted that this is the way forward, we can deliver to them our technology and make that happen. It’s the most efficient way without spending or paying out too much.

For more of our discussion, you can watch the whole Fireside Chat with Andreas Weber, or listen to the podcast version, below.

To check out previous Fireside Chats and to make sure that you don’t miss any future updates, subscribe to our newsletter or follow us on YouTube, LinkedIn, Twitter, Facebook or our podcast. If you enjoyed this episode, kindly leave a review on iTunes.

About Impetus Digital

Impetus Digital is the spark behind sustained healthcare stakeholder communication, collaboration, education, and insight synthesis. Our best-in-class technology and professional services ensure that life science organizations around the world can easily and cost-effectively grow and prosper—from brand or idea discovery to development, commercialization, execution, and beyond—in collaboration with colleagues, customers, healthcare providers, payers, and patients.